Drugs In Myocardial Infarction Research Articles

The impact of using P6 acupressure on the nausea, vomiting, and comfort of myocardial infarction patients: A randomized, single-blind, placebo-controlled clinical trial

BackgroundNausea and vomiting are two common symptoms in myocardial infarction patients. This study aims to determine the impact of p6 acupressure on nausea, vomiting, comfort, and the need for anti-vomiting drugs in myocardial infarction (MI) patients. MethodsThis research involved 90 patients with acute heart attacks experiencing persistent nausea despite taking anti-vomiting drugs. They were divided into three groups: acupressure, placebo, and control. The acupressure group wore a wristband with a button, the placebo group had a similar wristband without a button, and the control group received no wristband. Data on nausea severity, comfort, frequency of nausea, vomiting, and retching was collected before and after the intervention at different time points. The study also assessed the use of anti-vomiting drugs within 24 h of the intervention. ResultsThe patients in the acupressure group, compared to those in the placebo and control groups, experienced significantly lower severity of nausea, frequency of vomiting, nausea, and retching and a substantially higher level of comfort level during the two, four, and 6 h after the start of the intervention (P < 0.05). However, no significant difference between the placebo and control groups was observed (P > 0.05). During the 24 h after the start of the intervention, administration of anti-vomiting drugs to the acupressure group was significantly less than that done in the placebo and control groups (P < 0.05). ConclusionsThe results illustrated that p6 acupressure reduces nausea, vomiting, and retching and increases the comfort level in myocardial infarction patients.

Extensive heterogeneity of human urokinase, as detected by two-dimensional mapping.

Urokinase (uPA, urinary plasminogen activator) is a serine protease belonging to the peptidase S1 family. Specifically, uPA cleaves the zymogen plasminogen into the active form (plasmin), which then degrades the fibrin clots. It is widely used as a fibrinolytic agent in thrombolytic therapy and it is also used clinically as a thrombolytic agent. It can be administered to improve the drainage of complicated pleural effusions and empyemas and it is the most effective drug in myocardial infarction. The enzyme was originally identified in human urine for its ability to catalyze the transformation of plasminogen into its active form (plasmin), which degrades fibrin and extracellular matrix components. The present report deals with the analysis and characterization of this preparation.

CHANGES IN PREHOSPITAL PHARMACOTHERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN 2005-2014 ACCORDING TO THE LIS REGISTER

Aim. To study changes in prehospital pharmacotherapy with cardiovascular drugs in patients admitted to hospital with acute coronary syndrome (ACS) in 2005-2014. Material and methods. The data of the LIS register (Lyubertsy study of mortality in patients undergone acute myocardial infarction) were used. Patients that survived 4 days after admission were included in the analysis. Results. The positive changes in the prescription of antiplatelet agents (13.5% in 2005 and 27.4% in 2014), statins (1.7% and 16.3%, respectively) and angiotensin receptor blockers (0.6% and 8.8%, respectively) were found. The prescription rate of other cardiovascular drug classes did not change significantly. Conclusion. Registration of treatment prior to ACS can be an important tool for evaluation of quality of ACS and myocardial infarction drug prevention.

Editor's Choice

Editor's Choice

Surival following thrombolytic therapy

The results of the major mortality studies of thrombolytic drugs in myocardial infarction demonstrate that streptokinase, APSAC and t-PA reduce mortality significantly. Large studies (GISSI-2 comparing Genentech t-PA with streptokinase and ISIS-3 comparing streptokinase, APSAC and Wellcome t-PA) are currently under way to identify which, if any, of the above agents is the most effective. Review of the results of the reported studies has emphasized the importance of treatment being given as soon as practical after the onset of symptoms. It has also revealed that substantial benefit is achievable in patients often not considered to be candidates for thrombolytic therapy, such as those presenting for treatment between 6 and 24 h after symptom onset, and elderly patients. It is emphasized that important benefit may be missed in clinical practice in deciding who should, or should not, receive thrombolytic drug therapy by complying too rigidly to what were investigative clinical study entry criteria.

Thrombolytic drugs in myocardial infarction.

Thrombolytic drugs in myocardial infarction.

Precardiac mapping in assessing the effect of drugs in myocardial infarction

A reliable instrumental method for assessing the effectiveness of the effect of drug therapy on the clinical course of myocardial infarction is precordial mapping (precordial electropolycardiography) in 35 chest leads.

Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis.

1 Dipyridamole (0.01 to 0.75 mM) increased prostacyclin (PGI2) biosynthesis from tritiated arachidonic acid in rat stomach fundus homogenates by 21 to 350%. The transformation of prostaglandin H2 (PGH2) to PGI2 by a microsomal fraction of pig aorta was stimulated by dipyridamole at 0.1 M by 63%. 2 In the isolated perfused heart of the rabbit dipyridamole at 1 and 5 micrograms/ml increased PGI2 release by 70% and 146% respectively. 3 Our results show a stimulation of the second step in PGI2 biosynthesis (from endoperoxides) by dipyridamole. This effect should be considered in relation to the therapeutic usage of the drug in myocardial infarction.

Vasoconstrictor drugs in myocardial infarction

In our issue of September 18, we discussed the use of vasoconstrictor drugs in myocardial infarction (Drug Ther. Bull. p. 73), pointing out the theoretical reasons for doubting their advisability, though many clinicians think that noradrenaline is of value. Since then two papers have appeared which reinforce our arguments.